On May 14, 2018, the Federal Circuit affirmed the Patent Trial and Appeal Board’s (the “Board”) Final Written Decision in an inter partes review (IPR) proceeding holding all claims of Anacor Pharmaceuticals, Inc.’s (“Anacor”)...more
The Patent Trial and Appeal Board (PTAB) denied Pfizer, Inc.’s (“Petitioner”) petition to institute an inter partes review (IPR) of the sole claim of Biogen Inc.’s (“Patent Owner”) U.S. Patent 8,329,172 (the “’172 Patent”)....more
The Patent Trial and Appeal Board (the “Board”) issued a final written decision in an inter partes review determining Claims 1-5 of U.S. Patent No. 8,889,135 owned by Abbvie Biotechnology Ltd. unpatentable as obvious...more
7/11/2017
/ AbbVie ,
Boehringer ,
Final Written Decisions ,
Inter Partes Review (IPR) Proceeding ,
Method Claims ,
Obviousness ,
Patent Invalidity ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Prior Art
The Patent Trial and Appeal Board (the “Board”) issued a final written decision determining that the Coalition for Affordable Drugs (ADROCA), LLC (“Petitioner”) failed to prove unpatentable claims 1-52 of U.S. Patent No....more
4/12/2017
/ Burden of Production ,
Expert Testimony ,
Inter Partes Review (IPR) Proceeding ,
Inventors ,
Obviousness ,
Patent Invalidity ,
Patent Ownership ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Prior Art
DISTRICT COURT CASES -
Minnesota Court Awards Octane Fitness $1.7 Million in Attorney Fees and Costs -
In the seminal case establishing a lower standard for attorney fees in “exceptional” patent cases—Octane Fitness...more
9/8/2015
/ America Invents Act ,
Anti-Patent Trolls ,
Attorney's Fees ,
Counterclaims ,
Covered Business Method Patents ,
Demand Letter ,
Exceptional Case ,
Inter Partes Review (IPR) Proceeding ,
MasterCard ,
Method Claims ,
Motion to Amend ,
Octane Fitness v. ICON ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent Trolls ,
Patents ,
Prior Art
SUPREME COURT CASES -
The Supreme Court Upholds Prohibition on Charging Royalties After Patent Expiration -
In Kimble v. Marvel Entertainment LLC, 576 U.S. ---- (2015), the Supreme Court declined to overrule its 1964...more
8/31/2015
/ Akamai Technologies ,
Brulotte ,
Certiorari ,
Claim Construction ,
Contract Termination ,
Contract Terms ,
Direct Infringement ,
En Banc Review ,
Inter Partes Review (IPR) Proceeding ,
IP License ,
Kimble v Marvel Enterprises ,
Limelight Networks ,
Limelight v Akamai ,
Mayo v. Prometheus ,
Obviousness ,
Patent Infringement ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prior Art ,
Remand ,
Royalties ,
SCOTUS ,
Section 101